Details for Patent: 11,959,486
✉ Email this page to a colleague
Which drugs does patent 11,959,486 protect, and when does it expire?
Patent 11,959,486 protects PARSABIV and is included in one NDA.
This patent has forty-seven patent family members in thirty-eight countries.
Drugs Protected by US Patent 11,959,486
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-001 | Feb 7, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT) | ⤷ Sign Up | |||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-002 | Feb 7, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT) | ⤷ Sign Up | |||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT) | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,959,486
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 096773 | ⤷ Sign Up | |||
| Australia | 2014302122 | ⤷ Sign Up | |||
| Brazil | 112015032615 | ⤷ Sign Up | |||
| Canada | 2916222 | ⤷ Sign Up | |||
| Chile | 2015003738 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
